Our Board of Directors

Greg Beniston BA, LLB
Chairman Of the Board
Mr. Beniston, 52, is an experienced counsel with expertise in technology, corporate/commercial, securities, corporate governance and aviation. He was Legal Counsel and Corporate Secretary for Xillix Technologies Corp. a cancer imaging company from 1993 until 2000 and was Vice President Legal and Corporate Secretary of MDSI Mobile Data Solutions Inc. from 1996 to 2003. Since 2006 Mr. Beniston has been employed by CHC Helicopter Group Of Companies as Senior Legal Counsel.


Douglas Wallis CA
A Chartered Accountant for over 30 years, Doug Wallis specializes in work with Canadian and US public companies. Doug received his CA after completing a five year post secondary education articling program. His work involves everything from assisting in the structure of initial public offerings to comprehensive audit services. Doug's extensive experience in accounting and the rules of professional conduct are also highly valued at Smythe Ratcliffe LLP. As a partner heavily involved in Professional Standards, he brings a commitment to integrity, professionalism and quality that permeates throughout the entire leadership team. Previously, Doug was the Director of Professional Advisory Services, Institute of Chartered Accountants of BC.
Besides his work at Smythe Ratcliffe, Doug is the Past Chairman of the Board for the Canadian Network for International Surgery (CNIS).


Wendi Rodrigueza PhD.
Dr. Rodrigueza, brings years of drug development experience to the Issuer's Board of Directors. From 1994 - 1998 she conducted post doctorate fellow studies at Thomas Jefferson University and The Medical College of Pennsylvania. Wendi received her Ph.D. from the University of British Columbia in 1994. From 1998 to 2003 she was employed by Espirion Therapeutics Inc. culminating in the position of Director, Product Development. Dr. Rodrigueza was a co-inventor of the technology Esperion was founded on. Esprion was sold to Pfizer Global Research and Development for $1.3 billion in 2003. She is currently the VP of Drug Development for ProNAi Therapeutics and since 2003 has been a consultant to several companies including CuraGen Corporation, and Novartis Institute of Biomedical Research.


Douglas H. Unwin B.Sc., MBA
President and Chief Executive Officer
Mr. Unwin, 53, is our founder and has served as President and Chief Executive Officer since the Issuer's inception in September 2005. He is a fulltime employee of the Issuer and devotes the majority of his working hours to the Issuer's business. Mr. Unwin is responsible for the Issuer's overall strategic direction and the implementation of that strategy. He is based at the Issuer's head office in Vancouver, British Columbia. Mr. Unwin is an experienced executive with 18 years of diverse experience including 16 years as an entrepreneur in Life Sciences, Aquaculture and Telecommunications. He has spent his last 6 years focused on Life Science start-ups, technology commercialization and venture capital financing. Mr. Unwin was an Associate with Neuro Discovery Inc. a venture capital company focused on investing in therapies for neurological disorders. During his tenure Mr. Unwin reviewed numerous business plans and assisted in the structuring of investments. Mr. Unwin developed the original business models that evolved into a successful specialty pharma. Prior to founding the Issuer, Mr. Unwin was the CEO of Med BioGene Inc. (MBI.TSX Venture) a start-up medical device company.